Laruparetigene zovaparvovec is under clinical development by Applied Genetic Technologies and currently in Phase II for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase II drugs for Retinitis Pigmentosa (Retinitis) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Laruparetigene zovaparvovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Laruparetigene zovaparvovec overview

Laruparetigene zovaparvovec (AGTC-501) is under development for the treatment of X-linked retinitis pigmentosa (XLRP). It is administered through subretinal injection and acts by targeting X-linked retinitis pigmentosa GTPase regulator (RPGR). The gene therapy is developed based on adeno-associated virus (AAV) vector technology platform.

Applied Genetic Technologies overview

Applied Genetic Technologies (AGTC) is a pharmaceutical company. The company Invovled in development of eye disease cures. AGTC develops treatments for patients that have diseases caused by broken genes. It offers products such X-linked retinitis pigmentosa, achromatopsia, bionic sight, age-related macular degeneration,non-syndromic hearing loss and deafness,frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company’s achromatopsia provides treatment for inherited conditions that are associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and total loss of color discrimination. AGTC’s x-linked retinoschisis offers treatment in retinal degeneration affecting young males, presenting with poor vision by school age. The company also offers ophthalmology development programs and proof-of-concept data in multiple indications. AGTC is headquartered in Alachua, Florida, the US

For a complete picture of Laruparetigene zovaparvovec’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.